drugset / Trial / NCT00637559

Barrett's Esophagus - 315 - 3 Way Cross-Over

NCT00637559

Phase 4 Completed 50 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.

Timeline

Start
2002-03
Primary completion
2003-04
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg
Subject Esomeprazole Small molecule 40 mg

Indications